Others

Aurobindo Pharma Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

| Updated on November 12, 2018 Published on November 12, 2018

Our wholly owned subsidiary, Aurobindo Pharma USA Inc., USA, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty Ltd., Australia, through AuroScience Pty Limited, Melbourne, a 100% subsidiary of Aurobindo Pharma USA Inc., USA. The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure A.

Pdf Link: Aurobindo Pharma Ltd. - Announcement under Regulation 30 (LODR)-Acquisition

Source : BSE - www.bseindia.com

Published on November 12, 2018
This article is closed for comments.
Please Email the Editor